Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 16/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28039015 | 0.78 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL8855985 | 0.75 | KCNH2 (0.38) | — | |
| SCHEMBL13469961 | 0.74 | PRF1 (0.65) | PRF1MAPTLMNAGAAACHE | |
| SCHEMBL5017018 | 0.74 | PRF1 (0.56) | PRF1MAPTLMNAGAAACHE | |
| SCHEMBL105809 | 0.73 | NPC1 (0.41) | — | |
| SCHEMBL6484620 | 0.72 | PRF1 (0.51) | PRF1MAPTLMNAGAAACHE | |
| SCHEMBL9919011 | 0.72 | P2RX7 (0.36) | PRF1 | |
| SCHEMBL132013 | 0.72 | KCNH2 (0.49) | — | |
| SCHEMBL16573996 | 0.71 | PRF1 (0.61) | PRF1MAPTLMNAGAAACHE | |
| SCHEMBL19966686 | 0.71 | PRF1 (0.61) | PRF1MAPTLMNAGAAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911548-B2 | Method for the preparation of 5-cyanophthalide | H. LUNDBECK A/S (DK) | 2005-06-28 | — | — | US | claimed |
| EP-1254129-B1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | claimed |
| US-20030013895-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2003-01-16 | — | — | US | claimed |
| EP-1123284-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2003-01-08 | — | — | EP | claimed |
| US-6365747-B1 | BY THERMALLY CLEAVING THE THIAZOLINE RING, OR TREATMENT IN PRESENCE OF A RADICAL INITIATOR; ONE-POT PROCESS; BY-PRODUCT INHIBITION; ANTIDEPRESSANT; PREFERENTIAL, CENTRALLY ACTING SEROTONIN (5-HYDROXYTRYPTAMINE; 5-HT) REUPTAKE INHIBITOR; | H. LUNDBECK A/S (DK) | 2002-04-02 | — | — | US | claimed |
| EP-1700851-B1 | CRYSTALLINE CITALOPRAM DIOL INTERMEDIATE ALKALI | HANGZHOU MINSHENG PHARM CO LTD (CN) | 2012-09-12 | — | — | EP | disclosed |
| US-7435838-B2 | Crystalline citalopram diol intermediate alkali | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD. (CN) | 2008-10-14 | — | — | US | disclosed |
| US-20070117992-A1 | Crystalline citalopram diol intermediate alkali | ZHEJIANG HONGGUAN BIO-PHARMA CO., LTD. (CN) | 2007-05-24 | — | — | US | disclosed |
| EP-1700851-A1 | CRYSTALLINE CITALOPRAM DIOL INTERMEDIATE ALKALI | Hangzhou Minsheng Pharm. Co., Ltd. (CN) | 2006-09-13 | — | — | EP | disclosed |
| US-6911548-B2 | Method for the preparation of 5-cyanophthalide | H. LUNDBECK A/S (DK) | 2005-06-28 | — | — | US | disclosed |
| EP-1254129-B1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | disclosed |
| US-20030013895-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | H. LUNDBECK A/S (DK) | 2003-01-16 | — | — | US | disclosed |
| EP-1123284-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2003-01-08 | — | — | EP | disclosed |
| US-6365747-B1 | BY THERMALLY CLEAVING THE THIAZOLINE RING, OR TREATMENT IN PRESENCE OF A RADICAL INITIATOR; ONE-POT PROCESS; BY-PRODUCT INHIBITION; ANTIDEPRESSANT; PREFERENTIAL, CENTRALLY ACTING SEROTONIN (5-HYDROXYTRYPTAMINE; 5-HT) REUPTAKE INHIBITOR; | H. LUNDBECK A/S (DK) | 2002-04-02 | — | — | US | disclosed |
| EP-1123284-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023431-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117992-A1 | Crystalline citalopram diol intermediate alkali | HTR5A, HTR4, HTR3D | PRF1 4870/4885MAPT 290/4885LMNA 912/4885 |
| US-20030013895-A1 | METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE | CBR1, CBR3, CYC1 | PRF1 4325/4885MAPT 3619/4885LMNA 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.